NCT01923558已完成1 期
Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fasting State
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- Area under curve (AUC)
研究概览
简要总结
To evaluate and compare the relative bioavailability and therefore the bioequivalence of two different formulations of donepezil after a single oral dose administration under fasting conditions.
详细描述
Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover study under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female volunteer
- •Volunteer aged of at least 18 years but not older than 45 years
- •Volunteer with a body mass index (BMI) greater than or equal to 21 and below 30 kg/m2
- •Volunteer with a body weight greater than or equal to 60 kg.
- •Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes or less per day for at least 3 months before day 1 of this study. An ex-smoker is defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.
- •Availability for the entire study period
- •Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee.
- •Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
- •Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
- •Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer
- •Exclusion Criteria
- •Seated pulse rate less than 50 bpm at screening
- •Seated blood pressure below 105/60 mmHg at screening
- •Seated blood pressure below 105/60 mmHg before drug administration
- •Females who are pregnant or are lactating
- •Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study
- •History of significant hypersensitivity to donepezil, piperidine derivatives, scopolamine, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- •Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
- •History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
- •Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- •Suicidal tendency, history of or disposition to seizures, state of confusion,clinically relevant psychiatric diseases
- •Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities.
- •Use of ASA or NSAIDs (or any product containing ASA or NSAIDs) in the previous 7 days before day 1 of this study
- •Use of diphenhydramine in the previous 10 hours before day 1 of this study
- •Known presence of rare hereditary problems of galactose and /or lactose intolerance
- •Known presence of glaucoma or a predisposition to angle-closure glaucoma
- •Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- •Any clinically significant illness in the previous 28 days before day 1 of this study
- •Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
- •Any history of tuberculosis and/or prophylaxis for tuberculosis
- •Positive urine screening of alcohol and/or drugs of abuse
- •Positive results to HIV, HBsAg or anti-HCV tests
- •Females who are pregnant according to a positive serum pregnancy test
- •Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.
- •Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
排除标准
- 未提供
研究组 & 干预措施
Donepezil Hydrochloride Tablets, 23 mg
Experimental
Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
干预措施: Donepezil (Drug)
Aricept
Active Comparator
Aricept® 23 mg tablet of Eisai Inc
干预措施: Donepezil (Drug)
结局指标
主要结局
Area under curve (AUC)
时间窗: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 24, 48 and 72 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed ConditionHealthyNCT01923259Dr. Reddy's Laboratories Limited94
已完成
1 期
Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mgBioequivalenceNCT05145608Alembic Pharmaceuticals Ltd.22
已完成
1 期
A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed ConditionsHealthyNCT00864890Actavis Inc.32
已完成
1 期
A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting ConditionsHealthyNCT00865085Actavis Inc.28
已完成
1 期
Fed Bioavailability Study of Lovastatin Tablets and Mevacor TabletsHealthyNCT00684723Mutual Pharmaceutical Company, Inc.54